The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Oligonucleotide Synthesis, Modification and Purification Services Market: Focus on Research, Diagnostic and Therapeutic Applications (2nd Edition), Distribution by Type of Manufacturing (Custom and Contract), Type of Oligonucleotide Manufactured (Antisense, siRNA, shRNA, miRNA and Others), Scale of Operation, Purpose of Production (In-house and Outsourced), Type of Operation, Size of Manufacturer, Key Therapeutic Areas and Key Geographical Regions: Industry Trends and Global Forecasts, 2021-2031

  • Lowest Price Guaranteed From USD 5,899

  • Published
    September 2021

  • Pages
    405

  • View Count
    22987

Example Insights

	Sanitized-Oligonucleotide-Synthesis-Modification-and-Purification-Services-Market-Context Sanitized-Oligonucleotide-Synthesis-Modification-and-Purification-Services-Market-Distribution-by-Geography Sanitized-Oligonucleotide-Synthesis-Modification-and-Purification-Services-Market-List-of-Oligonucleotide-Manufacturers 	Sanitized-Oligonucleotide-Synthesis-Modification-and-Purification-Services-Market-Distribution-by-Company-Size
	Sanitized-Oligonucleotide-Synthesis-Modification-and-Purification-Services-Market-Scale-of-Operation Sanitized-Oligonucleotide-Synthesis-Modification-and-Purification-Services-Market-Competitiveness-Analysis Sanitized-Oligonucleotide-Synthesis-Modification-and-Purification-Services-Market-Expansions 	Sanitized-Oligonucleotide-Synthesis-Modification-and-Purification-Services-Market-Potential-Strategic-Partners
Sanitized-Oligonucleotide-Synthesis-Modification-and-Purification-Services-Market-Capacity-Analysis Sanitized-Oligonucleotide-Synthesis-Modification-and-Purification-Services-Market-Demand-Vs-Supply-Analysis Sanitized-Oligonucleotide-Synthesis-Modification-and-Purification-Services-Market-Distribution-by-Application-Area Sanitized-Oligonucleotide-Synthesis-Modification-and-Purification-Services-Market-Distribution-by-Therapeutic-Area

Overview

Post the marketing of Vitravene®, the first antisense oligonucleotide-based therapy to receive approval (in 1998), various stakeholders have undertaken multiple research initiatives to verify the potential of oligonucleotides as therapeutic agents. The known applications of oligonucleotides in research and diagnostics, in addition to their therapeutic use, have significantly increased. It is worth mentioning that these molecules play a crucial role in genetic testing, molecular testing protocols and various analytical testing procedures, such as artificial gene synthesis and polymerase chain reaction. In fact, several preclinical and clinical studies have demonstrated the potential of oligonucleotides as a safe and effective treatment modality, owing to their unique characteristics, such as high target specificity and superior pharmacokinetic profile. , As a result, over 14 oligonucleotide-based therapies have been approved till date. Notable examples of recently approved products include (in reverse chronological order of year of approval) AMONDYS 45 (2021), Oxlumo™ (2020) and Viltepso™ (2020). Further, over 350 oligonucleotide-based therapies are currently being evaluated across different development stages.

Oligonucleotides are usually manufactured using chemical synthesis approaches, such as phosphoramidite synthesis and solid-phase synthesis (used for manufacturing small molecules). Given to the intricacy of the aforementioned synthesis procedures, production of oligonucleotides is often associated with several challenges, such as lack of purification and analytical expertise among the stakeholders. Presently, a significant portion of the existing manufacturing capabilities and expertise in this domain belong to contract service providers. Therefore, several researchers and therapy / diagnostic developers engaged in this domain prefer to outsource their oligonucleotide manufacturing operations. Moreover, with the rise in global disease burden, there has been an increase in the demand for effective targeted therapies. Specifically, post the onset of the COVID-19 pandemic, there has been a significant rise in the demand for oligonucleotides, given their use in COVID-19 testing kits. Consequently, contract service providers are expanding their existing capacities and capabilities in order to cater to the growing demand. In addition, we believe that encouraging clinical trial results and extensive research activity related to oligonucleotides, coupled to their growing demand, is likely to result in lucrative opportunities for custom / contract service providers, in the foreseen future.

Scope of the Report

The “Oligonucleotide Synthesis, Modification and Purification Services Market: Focus on Research, Diagnostic and Therapeutic Applications (2nd Edition), Distribution by Type of Manufacturing (Custom Manufacturing and Contract Manufacturing), Type of Oligonucleotide Manufactured (Antisense, siRNA, shRNA, miRNA and Others), Scale of Operation (Clinical and Commercial), Purpose of Production (In-house Operations and Outsourced Operations), Type of Operation (API and FDF), Size of Manufacturer (Small, Mid-sized and Large), Key Therapeutic Areas (Autoimmune Disorders, Cardiovascular Disorders, Genetic Disorders, Infectious Diseases, Metabolic Disorders, Neuromuscular Disorders, Oncological Disorders, Ophthalmic Disorders, And Other Therapeutic Areas) and Key Geographical Regions  (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2021-2031” report features a detailed study of the current scenario and future potential of the custom synthesis, modification and purification services market for oligonucleotides, which are intended for research, diagnostic, and therapeutic applications. Further, the study underlines an in-depth analysis, highlighting the capabilities of service providers engaged in this domain. In addition to other elements, the study covers:

  • A detailed overview of the current market landscape of oligonucleotide manufacturers focused on research and diagnostic and therapeutic applications, based on several relevant parameters, such as year of establishment, company size, scale of operation (preclinical, clinical, and commercial), location of headquarters, number of manufacturing facilities, along with information on the location of facility (country-wise), regulatory accreditations and certifications received, type of oligonucleotide manufactured (antisense oligonucleotides, aptamers, decoys, miRNA, shRNA, siRNA, specialty amidites and others), type of offering (custom synthesis, modification and purification), type of manufacturing service(s) offered (process development and characterization, method validation and testing, analytical development, sequencing capabilities, stability studies, quality assurance and control, fill / finish, regulatory support, data analytics and reporting, and others), type of modification(s) offered (amino modifiers, backbone modifications, fluorescent probes, dyes and quenchers, modified bases, phosphorylation, thiol modifications and others) and type of purification method(s) used (desalting, cartridge purification, HPLC, ion exchange purification, PAGE and others).
  • An insightful company competitiveness analysis, highlighting the key oligonucleotide manufacturers focused on research and diagnostic, and therapeutic applications, based on supplier strength (on the basis of size of employee base and its experience) and service strength (on the basis of scale of operation, type of oligonucleotide manufactured, type of offering, type of manufacturing service(s) offered, type of modification(s) offered, type of purification method(s) used, and number and location of manufacturing facilities).
  • Elaborate profiles of key players engaged in offering custom synthesis, modification and purification of oligonucleotides for research and diagnostic, and therapeutic applications. Each profile includes an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, details on partnerships inked, recent developments and an informed future outlook.
  • A qualitative analysis highlighting the various factors that need to be considered by players engaged in this domain, while deciding whether to manufacture their respective products in-house or engage the services of a service provider.
  • A detailed review of the various oligonucleotide-based manufacturing initiatives undertaken by big pharma players (on the basis of revenues generated by top 5 pharmaceutical companies in 2020), highlighting trends across parameters, such as year of initiative, type of initiative and type of oligonucleotide.
  • An analysis of recent partnerships inked between players engaged in oligonucleotide manufacturing, during the period 2014-2021, based on several parameters, such as year of partnership, type of partnership, type of partner, most active players (in terms of number of partnerships signed), and region.
  • An analysis of the various expansion initiatives undertaken by service providers engaged in this domain, during the period 2016-2021, along with information on several relevant parameters, such as year of expansion, type of expansion (capability expansion, capacity expansion, facility expansion and new facility), scale of operation (preclinical, clinical and commercial), type of application (research and manufacturing operations), and location of manufacturing facility. 
  • An in-depth analysis of over 90 oligonucleotide-based therapy developers that are likely to partner with contract service providers engaged in this domain, based on several relevant parameters, such as developer strength (on the basis of company size and its experience), pipeline strength and maturity (on the basis of number of drugs in pipeline and their stage of development) and other manufacturing capabilities.
  • A detailed analysis of completed and ongoing clinical research studies of various oligonucleotide-based drugs, based on several relevant parameters, such as trial registration year, phase of development, type of oligonucleotide, current trial recruitment status, study focus area, key therapeutic areas (in terms of number of trials undertaken / conducted), enrolled patient population and trial location, and leading industry and non-industry players (in terms of number of trials undertaken / conducted).
  • An estimate of the global, installed capacity for the manufacturing of oligonucleotides, based on information provided by various industry stakeholders in the public domain. It also features distribution of available oligonucleotide synthesis capacity on the basis of company size (small, mid-sized and large firms), scale of operation (preclinical, clinical and commercial), and key geographical regions (North America, Europe, Asia-Pacific and rest of the world).
  • An informed estimate of the annual commercial demand for oligonucleotide-based drugs (in kilograms), based on several relevant parameters, such as target patient population, dosing frequency and dose strength. The annual clinical demand for oligonucleotide-based drug products was also estimated, taking into account ongoing clinical trials.
  • An elaborate discussion on how the recent COVID-19 pandemic is likely to impact the oligonucleotide synthesis market, along with information on the key initiatives undertaken by players engaged in this domain to overcome the challenges faced due to the pandemic.
  • A discussion on affiliated trends, key drivers and challenges, under an elaborate SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry.
  • A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing custom synthesis, modification and purification services for oligonucleotides.

One of the key objectives of this report was to evaluate the current opportunity and the future potential within the oligonucleotide synthesis, modification and purification services market, over the next decade. Based on multiple parameters, such as anticipated growth in number of oligonucleotide-focused projects, cost of goods sold, and direct manufacturing costs, we have developed informed estimates of the likely evolution of the market over the coming decade. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] type of manufacturing (custom manufacturing, and contract manufacturing), [B] type of oligonucleotide manufactured (antisense oligonucleotides, miRNA, shRNA, siRNA, and others), [C] scale of operation (clinical and commercial), [D] purpose of production (in-house operations and outsourced operations), [E] type of operation (active pharmaceutical ingredient (API) and finished dosage form (FDF)) [F] size of manufacturer (small, mid-sized, and large companies), [G] key therapeutic areas (autoimmune disorders, cardiovascular disorders, genetic disorders, infectious diseases, metabolic disorders, neuromuscular disorders, oncological disorders, ophthalmic disorders, and other therapeutic areas), and [H] key geographical regions (North America, Europe, and Asia-Pacific and rest of the world). In order to account for the uncertainties associated with the growth of the oligonucleotide synthesis, modification and purification services market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions presented in this study were influenced by inputs (through an industry-wide survey) of several key players in this domain. In addition, the report features detailed transcripts of interviews held with the following individuals:

  • Arun Shastry (Co-Founder and Managing Director, Hanugen Therapeutics)
  • Hans-Peter Vornlocher (Managing Director, Axolabs)
  • Joachim Bertram (Chief Scientific Officer and Managing Director, IBA Life Sciences)
  • Tobias Pohlmann (Founder and Managing Director, BianoScience)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading players offering oligonucleotide synthesis, modification and purification services for research, diagnostic and therapeutic applications?
  • What are the preferred modification and purification methods used for oligonucleotides?
  • What are the key challenges faced by stakeholders engaged in this domain?
  • What kind of partnership models are commonly adopted by industry stakeholders?
  • What are the recent expansion initiatives undertaken by service providers within this domain? 
  • Which therapy developers are likely to partner with oligonucleotide manufacturing service providers?
  • What is the annual, clinical and commercial demand for oligonucleotides?
  • What is the current, installed manufacturing capacity for oligonucleotides?
  • What percentage of oligonucleotide manufacturing operations are outsourced to service providers?
  • What factors should be taken into consideration while deciding whether the manufacturing operations for oligonucleotides should be kept in-house or outsourced?
  • What are the different initiatives undertaken by big pharma players engaged in this domain, in the recent past?
  • What are the opportunities in emerging markets for oligonucleotide manufacturing?
  • How is the current and future market opportunity likely to be distributed across key market segments?
  • What are the anticipated future trends related to oligonucleotide manufacturing?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the likely evolution of the oligonucleotide synthesis, modification and purification services market in the mid-long term.

Chapter 3 presents a general introduction to oligonucleotides, featuring information on the oligonucleotide-based products available in the market. Further, it features a detailed discussion on different steps involved in custom synthesis, chemical modification and purification of oligonucleotides, along with information on the key challenges associated. In addition, the chapter includes a brief discussion on the need for outsourcing within the oligonucleotides market. Furthermore, it lists the commonly outsourced oligonucleotide synthesis, modification and purification operations, along with information on the key factors that need to be considered while selecting a service provider. The chapter concludes with a discussion on the key growth drivers and roadblocks associated with oligonucleotide manufacturing, as well as upcoming trends in this field.

Chapter 4 provides a detailed review of the current status of the market with respect to oligonucleotide manufacturers focused on research and diagnostic applications. The chapter features information on the year of establishment, company size, scale of operation (small, medium, and large), location of headquarters, number of manufacturing facilities, along with their locations (country-wise), and regulatory accreditations and certifications received by them, type of oligonucleotide manufactured (antisense oligonucleotides, aptamers, decoys, miRNA, shRNA, siRNA, specialty amidites, and others), type of offering (custom synthesis, modification and purification), type of manufacturing service(s) offered (process development and characterization, method validation and testing, analytical development, sequencing capabilities, stability studies, quality assurance and control, scale-up, fill / finish, downstream processing, regulatory support, data analytics and reporting, and others), type of modification(s) offered (amino modifiers, backbone modifications, fluorescent probes, dyes and quenchers, modified bases, phosphorylation, thiol modifications, and others) and type of purification method(s) used (desalting, cartridge purification, HPLC, ion exchange purification, PAGE, and others).

Chapter 5 provides a detailed review of the current status of the market with respect to oligonucleotide manufacturers focused on therapeutic applications. The chapter features information on the year of establishment, company size, scale of operation (preclinical, clinical, and commercial), location of headquarters, number of manufacturing facilities, along with their locations (country-wise), and regulatory accreditations and certifications received by them, type of oligonucleotide manufactured (antisense oligonucleotides, aptamers, decoys, miRNA, shRNA, siRNA, specialty amidites, and others), type of offering (custom synthesis, modification and purification), type of manufacturing service(s) offered (process development and characterization, method validation and testing, analytical development, sequencing capabilities, stability studies, quality assurance and control, fill/finish, regulatory support, data analytics and reporting, and others), type of modification(s) offered (amino modifiers, backbone modifications, fluorescent probes, dyes and quenchers, modified bases, phosphorylation, thiol modifications, and others) and type of purification method(s) used (desalting, cartridge purification, HPLC, ion exchange purification, PAGE, and others).

Chapter 6 features an insightful company competitiveness analysis of oligonucleotide manufacturers for research and diagnostic applications, based in North America, Europe and Asia-Pacific, that we came across during our research. The analysis compares companies within each geography on the basis of supplier strength (which was calculated by considering the size of employee base of a company and its experience in this field) and service strength (quantified based on scale of operation, expertise in manufacturing different types of oligonucleotides, type of offering, type of manufacturing service(s) offered, type of modification(s) offered, type of purification method(s) used, as well as number and location of manufacturing facilities). 

Chapter 7 features an insightful company competitiveness analysis of oligonucleotide manufacturers for therapeutic applications, based in North America, Europe and Asia-Pacific, that we came across during our research. The analysis compares companies within each geography on the basis of supplier strength (which was calculated by considering the size of employee base of a company and its experience in this field) and service strength (quantified based on scale of operation, expertise in manufacturing different types of oligonucleotides, type of offering, type of manufacturing service(s) offered, type of modification(s) offered, type of purification method(s) used, as well as number and location of manufacturing facilities).

Chapter 8 includes elaborate profiles of key industry players (shortlisted on the basis of company competitiveness analysis scores) that offer a diverse range of capabilities for the custom synthesis, modification and purification of oligonucleotides for use in research and diagnostic applications. Each profile includes an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, details on partnerships, recent developments (expansions), and awards received by the firm, as well as an informed future outlook.

Chapter 9 includes elaborate profiles of key industry players (shortlisted on the basis of company competitiveness analysis scores) that offer a diverse range of capabilities for the custom synthesis, modification and purification of oligonucleotides for use in therapeutic applications. Each profile includes an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, details on partnerships, recent developments (expansions), and awards received by the firm, as well as an informed future outlook.

Chapter 10 presents a qualitative analysis highlighting the various factors that need to be taken into consideration by oligonucleotide-based therapy developers, while deciding whether to manufacture their respective products in-house or engage the services of a service provider.

Chapter 11 provides a detailed analysis of oligonucleotide-based manufacturing related initiatives of the big pharma players (shortlisted on the basis of the revenues generated by the top 5 pharmaceutical companies in 2020), featuring trends across various parameters, such as year of initiative, type of initiative and type of oligonucleotide.

Chapter 12 features an elaborate analysis of the various partnerships and collaborations that have been inked amongst players in this domain, in the time period 2014-2021. It provides a brief description on the various types of partnership models (which include asset purchase agreements, distribution agreements, manufacturing agreements, mergers / acquisitions, product development agreements, R&D agreements, service alliances, and others) that have been adopted by stakeholders in this domain. Further, it includes analyses based on the year of agreement, type of partner, and most active players. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 13 presents detailed analysis on the various expansion initiatives undertaken by service providers engaged in this domain, in order to augment their respective oligonucleotide manufacturing capabilities, over the period 2016-2021. It includes information on expansions carried out for increasing existing capabilities, as well as those intended for setting-up of new facilities by manufacturers engaged in this domain. The expansion instances that we came across were analyzed based on various parameters, including year of expansion, type of expansion (capability expansion, capacity expansion, facility expansion, and new facility), scale of operation (preclinical, clinical and commercial), application (research and manufacturing operations), and location of manufacturing facility. 

Chapter 14 features an in-depth analysis of more than 96 oligonucleotide-based therapy developers that are anticipated to partner with contract service providers and have been shortlisted on the basis of several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of other oligonucleotide-based therapy capabilities.

Chapter 15 provides a detailed analysis of completed and ongoing clinical research studies of various oligonucleotide-based drug products, highlighting prevalent trends across several relevant parameters, such as trial registration year, phase of development, type of oligonucleotide, current trial recruitment status, study focus area, key therapeutic areas (in terms of number of trials undertaken / conducted), enrolled patient population and trial location, and leading industry and non-industry players (in terms of number of trials undertaken / conducted).

Chapter 16 features a detailed analysis of the global / regional capacity of manufacturers that are engaged in the synthesis of oligonucleotides. The analysis takes into consideration the individual manufacturing capacities of various stakeholders (small, mid-sized, and large manufacturers) in the market, using data from both secondary and primary research. It also examines the likely distribution of the global oligonucleotide manufacturing capacity available across different types of companies (small, mid-sized, and large manufacturers), scales of operation (preclinical / clinical and commercial), and key geographical regions (North America, Europe, and Asia-Pacific and rest of the world).

Chapter 17 features a detailed estimate of the annual demand for oligonucleotide-based drug products (in kilograms), offering an informed opinion on the required scale of supply (in terms of oligonucleotide synthesis services). In order to estimate the annual commercial demand, we considered the marketed oligonucleotide products; the analysis takes into consideration the target patient population, dosing frequency and dose strength of the aforementioned products. The annual clinical demand for oligonucleotide-based drug products was also estimated, taking into account the ongoing clinical trials. 

Chapter 18 presents an insightful market forecast analysis, highlighting the likely growth of the oligonucleotide synthesis, modification and purification services market, till 2031. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] type of manufacturing (custom manufacturing, and contract manufacturing), [B] type of oligonucleotide manufactured (antisense oligonucleotides, miRNA, shRNA, siRNA, and others), [C] scale of operation (clinical and commercial), [D] purpose of production (in-house operations and outsourced operations), [E] type of operation (API and FDF) [F] size of manufacturer (small, mid-sized, and large companies), [G] key therapeutic areas (autoimmune disorders, cardiovascular disorders, genetic disorders, infectious diseases, metabolic disorders, neuromuscular disorders, oncological disorders, ophthalmic disorders, and other therapeutic areas), and [H] key geographical regions (North America, Europe, and Asia-Pacific and rest of the world) 

Chapter 19 features an insightful discussion on how the recent COVID-19 pandemic is likely to impact the oligonucleotide synthesis market, along with information on the key initiatives undertaken by the developers engaged in this domain to overcome the challenges faced due to the pandemic.

Chapter 20 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of oligonucleotide synthesis, modification and purification services market, under a detailed SWOT framework.

Chapter 21 presents the insights generated from a detailed survey, wherein we invited multiple stakeholders involved in the oligonucleotide synthesis, modification and purification services market.

Chapter 22 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with Hans-Peter Vornlocher (Managing Director, Axolabs), Tobias Pohlmann (Founder and Managing Director, BianoScience), Arun Shastry (Co-Founder and Managing Director, Hanugen Therapeutics) and Joachim Bertram (Chief Scientific Officer and Managing Director, IBA Life Sciences).

Chapter 23 is a summary of the entire report. It provides the key takeaways and presents our independent opinion of this market, based on the research and analysis described in the previous chapters. It also provides a recap of some of the upcoming future trends, which, we believe, are likely to influence the growth of oligonucleotide synthesis, modification and purification service providers. 

Chapter 24 is an appendix, which provides tabulated data and numbers for all the figures provided in the report. 

Chapter 25 is an appendix, which provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Context and Background
3.2. Overview of Oligonucleotide-based Products
3.3. Types of Oligonucleotides
3.3.1. Antisense Oligonucleotides
3.3.2. Aptamers
3.3.3. miRNA
3.3.4. shRNA
3.3.5. siRNA
3.3.6. Other Oligonucleotides

3.4. Custom Synthesis of Oligonucleotides
3.4.1. Process Development and Characterization
3.4.2. Analytical Method Development
3.4.3. Method Validation and Testing
3.4.4. Quality Control and Quality Assurance 
3.4.5. Key Challenges Associated with Custom Synthesis of Oligonucleotides

3.5. Chemical Modification of Oligonucleotides
3.5.1. Backbone Modification
3.5.2. Sugar Ring Modification

3.6. Purification of Oligonucleotides
3.6.1. Desalting
3.6.2. Cartridge Purification
3.6.3. Polyacrylamide Gel Electrophoresis (PAGE) 
3.6.4. High Performance Liquid Chromatography (HPLC)

3.7. Outsourcing Oligonucleotide Manufacturing 
3.7.1. Need for Outsourcing
3.7.2. Commonly Outsourced Operations
3.7.3. Advantages of Outsourcing Manufacturing Operations
3.7.4. Guidelines for Selecting a Service Provider
3.8. Growth Drivers and Roadblocks to Oligonucleotide Manufacturing
3.9. Recent Developments and Upcoming Trends

4. MARKET LANDSCAPE: OLIGONUCLEOTIDE MANUFACTURERES (RESEARCH AND DIAGNOSTIC APPLICATIONS)
4.1. Chapter Overview
4.2. Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Scale of Operation
4.2.4. Analysis by Geographical Location
4.2.5. Analysis by Location of Manufacturing Facilities
4.2.6. Analysis by Regulatory Accreditations / Certifications Received
4.2.7. Analysis by Type of Oligonucleotide Manufactured
4.2.8. Analysis by Type of Offering
4.2.9. Analysis by Type of Manufacturing Service(s) Offered
4.2.10. Analysis by Type of Modification(s) Offered
4.2.11. Analysis by Type of Purification Method(s) Used 

5. MARKET LANDSCAPE: OLIGONUCLEOTIDE MANUFACTURERES (THERAPEUTIC APPLICATIONS)
5.1. Chapter Overview
5.2. Oligonucleotide Manufacturers Focused on Therapeutic Applications: Overall Market Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Scale of Operation
5.2.4. Analysis by Geographical Location
5.2.5. Analysis by Location of Manufacturing Facilities
5.2.6. Analysis by Regulatory Accreditations / Certifications Received
5.2.7. Analysis by Type of Oligonucleotide Manufactured
5.2.8. Analysis by Type of Offering
5.2.9. Analysis by Type of Manufacturing Service(s) Offered
5.2.10. Analysis by Type of Modification(s) Offered
5.2.11. Analysis by Type of Purification Method(s) Used 

6. COMPANY COMPETITIVENESS ANALYSIS: OLIGONUCLEOTIDE MANUFACTURES (RESEARCH AND DIAGNOSTIC APPLICATIONS)
6.1. Chapter Overview
6.2. Key Assumptions and Methodology
6.3. Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Company Competitiveness Analysis
6.3.1. Oligonucleotide Manufacturers in North America
6.3.2. Oligonucleotide Manufacturers in Europe
6.3.3. Oligonucleotide Manufacturers in Asia-Pacific

7. COMPANY COMPETITIVENESS ANALYSIS: OLIGONUCLEOTIDE MANUFACTURERS (THERAPEUTIC APPLICATIONS)
7.1. Chapter Overview
7.2. Key Assumptions and Methodology
7.3. Oligonucleotide Manufacturers Focused on Therapeutic Applications: Company Competitiveness Analysis
7.3.1. Oligonucleotide Manufacturers in North America
7.3.2. Oligonucleotide Manufacturers in Europe
7.3.3. Oligonucleotide Manufacturers in Asia-Pacific

8. COMPANY PROFILES: OLIGONUCLEOTIDE MANUFACTURERS (RESEARCH AND DIAGNOSTIC APPLICATIONS)
8.1. Chapter Overview
8.2. North America
8.2.1. Ajinomoto Bio-Pharma Services
8.2.1.1. Company Overview
8.2.1.2. Financial Information
8.2.1.3. Service Portfolio
8.2.1.4. Manufacturing Facilities and Capabilities
8.2.1.5. Recent Developments and Future Outlook

8.2.2. Integrated DNA Technologies
8.2.2.1. Company Overview
8.2.2.2. Service Portfolio
8.2.2.3. Manufacturing Facilities and Capabilities
8.2.2.4. Recent Developments and Future Outlook

8.2.3. Sigma Aldrich
8.2.3.1. Company Overview
8.2.3.2. Service Portfolio
8.2.3.3. Manufacturing Facilities and Capabilities
8.2.3.4. Recent Developments and Future Outlook

8.2.4. Thermo Fisher Scientific
8.2.4.1. Company Overview
8.2.4.2. Financial Information
8.2.4.3. Service Portfolio
8.2.4.4. Manufacturing Facilities and Capabilities
8.2.4.5. Recent Developments and Future Outlook

8.3. Europe
8.3.1. BioSpring
8.3.1.1. Company Overview
8.3.1.2. Service Portfolio
8.3.1.3. Manufacturing Facilities and Capabilities
8.3.1.4. Recent Developments and Future Outlook

8.3.2. Kaneka Eurogentec
8.3.2.1. Company Overview
8.3.2.2. Financial Information
8.3.2.3. Service Portfolio
8.3.2.4. Manufacturing Facilities and Capabilities
8.3.2.5. Recent Developments and Future Outlook

8.3.3. Microsynth
8.3.3.1. Company Overview
8.3.3.2. Service Portfolio
8.3.3.3. Manufacturing Facilities and Capabilities
8.3.3.4. Recent Developments and Future Outlook

8.4. Asia-Pacific and RoW
8.4.1. Sumitomo Chemical
8.4.1.1. Company Overview
8.4.1.2. Financial Information
8.4.1.3. Service Portfolio
8.4.1.4. Manufacturing Facilities and Capabilities
8.4.1.5. Recent Developments and Future Outlook

9. COMPANY PROFILES: OLIGONUCLEOTIDE MANUFACTURERS (THERAPEUTIC APPLICATIONS)
9.1. Chapter Overview
9.2. North America
9.2.1. Agilent Technologies
9.2.1.1. Company Overview
9.2.1.2. Financial Information
9.2.1.3. Service Portfolio
9.2.1.4. Manufacturing Facilities and Capabilities
9.2.1.5. Recent Developments and Future Outlook

9.2.2. Nitto Denko Avecia
9.2.2.1. Company Overview
9.2.2.2. Financial Information
9.2.2.3. Service Portfolio
9.2.2.4. Manufacturing Facilities and Capabilities
9.2.2.5. Recent Developments and Future Outlook

9.2.3. TriLink Biotechnologies
9.2.3.1. Company Overview
9.2.3.2. Financial Information
9.2.3.3. Service Portfolio
9.2.3.4. Manufacturing Facilities and Capabilities
9.2.3.5. Recent Developments and Future Outlook

9.3. Europe
9.3.1. CordenPharma
9.3.1.1. Company Overview
9.3.1.2. Service Portfolio
9.3.1.3. Manufacturing Facilities and Capabilities
9.3.1.4. Recent Developments and Future Outlook

9.3.2. LGC, Biosearch Technologies
9.3.2.1. Company Overview
9.3.2.2. Service Portfolio
9.3.2.3. Manufacturing Facilities and Capabilities
9.3.2.4. Recent Developments and Future Outlook

9.3.3. Lonza
9.3.3.1. Company Overview
9.3.3.2. Financial Information
9.3.3.3. Service Portfolio
9.3.3.4. Manufacturing Facilities and Capabilities
9.3.3.5. Recent Developments and Future Outlook

9.4. Asia-Pacific
9.4.1. STA Pharmaceutical
9.4.1.1. Company Overview
9.4.1.2. Financial Information
9.4.1.3. Service Portfolio
9.4.1.4. Manufacturing Facilities and Capabilities
9.4.1.5. Recent Developments and Future Outlook

10. MAKE VERSUS BUY DECISION FRAMEWORK
10.1. Chapter Overview
10.2. Assumptions and Key Parameters 
10.3. Oligonucleotide Manufacturers: Make versus Buy Decision Making
10.3.1. Scenario 1
10.3.2. Scenario 2
10.3.3. Scenario 3
10.3.4. Scenario 4
10.4. Concluding Remarks

11. BIG PHARMA INITIATIVES
11.1. Chapter Overview
11.2. List of Oligonucleotide Manufacturing Initiatives 
11.2.1. Analysis by Year of Initiative
11.2.2. Analysis by Type of Initiative
11.2.3. Analysis by Type of Oligonucleotide

12. PARTNERSHIPS AND COLLABORATIONS
12.1. Chapter Overview
12.2. Partnership Models
12.3. Oligonucleotide Manufacturers: Recent Partnerships and Collaborations
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by Type of Partner
12.3.4. Most Active Players: Analysis by Number of Partnerships
12.3.5. Analysis by Region
12.3.5.1. Intercontinental and Intracontinental Agreements
12.3.5.2. Most Active Players: Analysis by Number of Partnerships and Region
12.3.6. Analysis by Year of Merger / Acquisition
12.3.7. Analysis by Type of Acquisition
12.3.8. Key Value Drivers

13. RECENT EXPANSIONS
13.1. Chapter Overview
13.2. Oligonucleotide Manufacturers: Recent Expansions
13.2.1. Analysis by Year of Expansion
13.2.2. Analysis by Type of Expansion
13.2.3. Analysis by Application
13.2.4. Analysis by Location of Facility
13.2.5. Analysis by Expanded Facility Area
13.2.6. Analysis by Expanded Scale of Operation
13.3.7. Most Active Players: Analysis by Number of Expansions
13.3.8. Analysis by Region
13.3.8.1. Continent-wise Distribution
13.3.8.2. Country-wise Distribution

14. LIKELY PARTNER ANALYSIS
14.1. Chapter Overview
14.2. Scoring Criteria and Key Assumptions
14.3. Scope and Methodology
14.4. Potential Strategic Partners
14.4.1. Likely Partners for Antisense Oligonucleotides Manufacturers
14.4.2. Likely Partners for siRNA Therapeutics Manufacturers
14.4.3. Likely Partners for miRNA Therapeutics Manufacturers
14.4.4. Likely Partners for shRNA and sshRNA Therapeutics Manufacturers

15. CLINICAL TRIAL ANALYSIS
15.1. Chapter Overview
15.2. Scope and Methodology
15.3. Oligonucleotide-based Drug Products: Clinical Trial Analysis
15.3.1. Analysis by Trial Registration Year
15.3.2. Analysis by Phase of Development
15.3.3. Analysis by Type of Oligonucleotide
15.3.4. Analysis by Phase of Development and Type of Oligonucleotide  
15.3.5. Analysis by Trial Recruitment Status
15.3.6. Analysis by Trial Focus Area
15.3.7. Analysis by Study Design
15.3.8. Geographical Analysis by Number of Clinical Trials
15.3.9. Geographical Analysis by Enrolled Patient Population
15.3.10. Analysis by Type of Sponsor / Collaborator
15.3.11. Most Active Players: Analysis by Number of Registered Trials

16. CAPACITY ANALYSIS
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Oligonucleotide Manufacturers: Global Installed Capacity
16.3.1. Analysis by Size of Manufacturer
16.3.2. Analysis by Scale of Operation
16.3.3. Analysis by Location of Manufacturing Facility

17. DEMAND ANALYSIS
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Global Demand for Oligonucleotide Manufacturing
17.3.1. Global Commercial Demand for Oligonucleotide Manufacturing
17.3.1.1. Analysis by Type of Oligonucleotide
17.3.1.2. Analysis by Target Therapeutic Area
17.3.1.3. Analysis by Region

17.3.2. Global Clinical Demand for Oligonucleotide Manufacturing
17.3.2.1. Analysis by Type of Oligonucleotide
17.3.2.2. Analysis by Phase of Development
17.3.2.3. Analysis by Target Therapeutic Area
17.3.2.4. Analysis by Region

17.4. Demand and Supply Analysis
17.4.1. Scenario 1
17.4.2. Scenario 2
17.4.3. Scenario 3

18. MARKET SIZING AND OPPORTUNITY ANALYSIS
18.1. Chapter Overview
18.2. Key Assumptions and Forecast Methodology
18.3. Global Oligonucleotide Manufacturing Market, 2021-2031
18.4. Oligonucleotide Manufacturing Market: Analysis by Type of Manufacturing, 2021-2031
18.4.1. Custom Oligonucleotide Manufacturing Market, 2021-2031
18.4.2. Large-scale Oligonucleotide Manufacturing Market, 2021-2031
18.4.2.1 Oligonucleotide Manufacturing Market: Analysis by Type of Oligonucleotide Manufactured, 2021-2031

18.4.2.1.1. Oligonucleotide Manufacturing Market for Antisense Oligonucleotides, 2021-2031
18.4.2.1.2. Oligonucleotide Manufacturing Market for miRNA, 2021-2031
18.4.2.1.3. Oligonucleotide Manufacturing Market for shRNA, 2021-2031
18.4.2.1.4. Oligonucleotide Manufacturing Market for siRNA, 2021-2031
18.4.2.1.5. Oligonucleotide Manufacturing Market for Other Oligonucleotides, 2021-2031

18.4.2.2. Oligonucleotide Manufacturing Market: Analysis by Scale of Operation, 2021-2031
18.4.2.2.1. Oligonucleotide Manufacturing Market for Clinical Scale Operations, 2021-2031
18.4.2.2.2. Oligonucleotide Manufacturing Market for Commercial Scale Operations, 2021-2031

18.4.2.3. Oligonucleotide Manufacturing Market: Analysis by Purpose of Production, 2021-2031
18.4.2.3.1. Oligonucleotide Manufacturing Market for In-House Operations, 2021-2031
18.4.2.3.2. Oligonucleotide Manufacturing Market for Outsourced Operations, 2021-2031

18.4.2.4. Oligonucleotide Manufacturing Market: Analysis by Type of Operation, 2021-2031
18.4.2.4.1. Oligonucleotide Manufacturing Market for Active Pharmaceutical Ingredients, 2021-2031
18.4.2.4.2. Oligonucleotide Manufacturing Market for Finished Dosage Form, 2021-2031

18.4.2.5. Oligonucleotide Manufacturing Market: Analysis by Target Therapeutic Area, 2021-2031
18.4.2.5.1. Oligonucleotide Manufacturing Market for Autoimmune Disorders, 2021-2031
18.4.2.5.2. Oligonucleotide Manufacturing Market for Cardiovascular Disorders, 2021-2031
18.4.2.5.3. Oligonucleotide Manufacturing Market for Genetic Disorders, 2021-2031
18.4.2.5.4. Oligonucleotide Manufacturing Market for Infectious Diseases, 2021-2031
18.4.2.5.5. Oligonucleotide Manufacturing Market for Metabolic Disorders, 2021-2031
18.4.2.5.6. Oligonucleotide Manufacturing Market for Neuromuscular Disorders, 2021-2031
18.4.2.5.7. Oligonucleotide Manufacturing Market for Oncological Disorders, 2021-2031
18.4.2.5.8. Oligonucleotide Manufacturing Market for Ophthalmic Disorders, 2021-2031
18.4.2.5.9. Oligonucleotide Manufacturing Market for Other Therapeutic Areas, 2021-2031

18.4.2.6. Oligonucleotide Manufacturing Market: Analysis by Size of Manufacturer, 2021-2031
18.4.2.6.1. Oligonucleotide Manufacturing Market for Small Companies, 2021-2031
18.4.2.6.2. Oligonucleotide Manufacturing Market for Mid-sized Companies, 2021-2031
18.4.2.6.3. Oligonucleotide Manufacturing Market for Large Companies, 2021-2031

18.4.2.7. Oligonucleotide Manufacturing Market: Analysis by Geography, 2021-2031
18.4.2.7.1. Oligonucleotide Manufacturing Market in North America, 2021-2031
18.4.2.7.2. Oligonucleotide Manufacturing Market in Europe, 2021-2031
18.4.2.7.3. Oligonucleotide Manufacturing Market in Asia-Pacific and Rest of the World, 2021-2031

19. IMPACT OF COVID-19 PANDEMIC ON OLIGONUCLEOTIDE SYNTHESIS MARKET
19.1. Chapter Overview
19.2. Impact of COVID-19 on Oligonucleotide Synthesis Market
19.2.1. Impact on Future Oligonucleotide Market Opportunity
19.3. Recuperative Initiatives of Key Players
19.4. Recuperative Strategies for Businesses
19.4.1. Strategies for Implementation in the Short / Mid Term
19.4.2. Strategies for Implementation in the Long Term

20. SWOT ANALYSIS
20.1. Chapter Overview
20.2. Comparison of SWOT Factors

21. SURVEY ANALYSIS
21.1. Chapter Overview
21.2. Overview of Respondents
21.2.1. Analysis by Seniority Level of Respondents

21.3. Analysis of Survey Insights
21.3.1. Analysis by Type of Offering
21.3.2. Analysis by Application
21.3.3. Analysis by Installed Manufacturing Capacity
21.3.4. Analysis by Location of Manufacturing Facility 
21.3.5. Analysis by Extent of Outsourcing
21.3.6. Analysis by Current Market Opportunity

22. EXECUTIVE INSIGHTS
22.1. Chapter Overview
22.2. Hanugen Therapeutics
22.2.1. Company Snapshot
22.2.2. Interview Transcript: Arun Shastry, Co-Founder and Managing Director 

22.3. Axolabs
22.3.1. Company Snapshot
22.3.2. Interview Transcript: Hans-Peter Vornlocher, Managing Director

22.4. IBA Life Sciences
22.4.1. Company Snapshot
22.4.2. Interview Transcript: Joachim Bertram, Chief Scientific Officer and Managing Director

22.5. BianoScience 
22.5.1. Company Snapshot
22.5.2. Interview Transcript: Tobias Pohlmann, Founder and Managing Director 

23. CONCLUDING REMARKS

24. APPENDIX 1: TABULATED DATA

25. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Classification of Oligonucleotides
Figure 3.2 Steps Involved in the Manufacturing of Oligonucleotides
Figure 3.3 Types of Chemical Modifications of Oligonucleotides
Figure 3.4 Types of Purification Methods Used for Oligonucleotides
Figure 3.5 Types of Standalone Service Providers
Figure 3.6 Type of Service(s) Offered by Oligonucleotide Manufacturers
Figure 3.7 Guidelines for Selecting a Service Provider
Figure 3.8 Key Growth Drivers and Roadblocks to Oligonucleotide Manufacturing
Figure 4.1 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Year of Establishment
Figure 4.2 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Company Size
Figure 4.3 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Scale of Operation
Figure 4.4 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Company Size and Scale of Operation
Figure 4.5 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Headquarters (Region-wise)
Figure 4.6 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Manufacturing Facilities (Country-wise)
Figure 4.7 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Regulatory Accreditations / Certifications Received
Figure 4.8 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Oligonucleotide Manufactured
Figure 4.9 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Offering
Figure 4.10 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Company Size and Type of Offering
Figure 4.11 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Oligonucleotide Manufactured and Type of Offering
Figure 4.12 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Year of Establishment, Company Size and Type of Offering
Figure 4.13 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Manufacturing Service(s) Offered
Figure 4.14 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Modification(s) Offered
Figure 4.15 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Purification Method(s) Used
Figure 5.1 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Year of Establishment
Figure 5.2 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Company Size
Figure 5.3 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Scale of Operation
Figure 5.4 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Company Size and Scale of Operation
Figure 5.5 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Headquarters (Region-wise)
Figure 5.6 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Manufacturing Facilities (Country-wise)
Figure 5.7 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Regulatory Accreditations / Certifications Received
Figure 5.8 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Oligonucleotide Manufactured
Figure 5.9 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Offering
Figure 5.10 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Company Size and Type of Offering
Figure 5.11 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Oligonucleotide Manufactured and Type of Offering
Figure 5.12 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Year of Establishment, Company Size and Type of Offering
Figure 5.13 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Manufacturing Service(s) Offered
Figure 5.14 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Modification(s) Offered
Figure 5.15 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Purification Method(s) Used
Figure 6.1 Company Competitiveness Analysis: Distribution of North America based Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications
Figure 6.2 Company Competitiveness Analysis: Distribution of Europe based Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications
Figure 6.3 Company Competitiveness Analysis: Distribution of Asia-Pacific based Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications
Figure 7.1 Company Competitiveness Analysis: Distribution of North America based Oligonucleotide Manufacturers Focused on Therapeutic Applications
Figure 7.2 Company Competitiveness Analysis: Distribution of Europe based Oligonucleotide Manufacturers Focused on Therapeutic Applications
Figure 7.3 Company Competitiveness Analysis: Distribution of Asia-Pacific and rest of the World based Oligonucleotide Manufacturers Focused on Therapeutic Applications
Figure 8.1 Ajinomoto Bio-Pharma Services: Annual Revenues (JPY Billion)
Figure 8.2 Thermo Fisher Scientific: Annual Revenues (USD Billion)
Figure 8.3 Kaneka Eurogentec: Annual Revenues (JPY Billion)
Figure 8.4 Sumitomo Chemical: Annual Revenues (JPY Billion)
Figure 9.1 Agilent Technologies: Annual Revenues (USD Billion)
Figure 9.2 Nitto Denko Avecia: Annual Revenues (USD Billion)
Figure 9.3 Trilink Biotechnologies: Annual Revenues (USD Billion)
Figure 9.4 Lonza: Annual Revenues (CHF Billion)
Figure 9.5 STA Pharmaceutical: Annual Revenues (RMB Billion)
Figure 10.1 Make versus Buy Decision Making Framework
Figure 10.2 Make versus Buy Decision Making: Possible Scenario Descriptions
Figure 11.1 Big Pharma Initiatives: Distribution by Year of Initiative
Figure 11.2 Big Pharma Initiatives: Distribution by Type of Initiative
Figure 11.3 Big Pharma Initiatives: Distribution by Type of Oligonucleotide Manufactured
Figure 12.1 Partnerships and Collaborations: Cumulative Distribution by Year of Partnership, 2014-2021
Figure 12.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 12.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 12.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 12.5 Most Active Players: Distribution by Number of Partnerships
Figure 12.6 Most Active Players: Geographical Distribution by Number of Partnerships
Figure 12.7 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 12.8 Mergers and Acquisitions: Distribution by Year of Merger / Acquisition
Figure 12.9 Mergers and Acquisitions: Distribution by Type of Acquisition
Figure 12.10 Mergers and Acquisitions: Key Value Drivers
Figure 13.1 Recent Expansions: Distribution by Year of Expansion, 2016-2021
Figure 13.2 Recent Expansions: Distribution by Type of Expansion
Figure 13.3 Recent Expansions: Distribution by Type Expansion and Purpose of Expansion
Figure 13.4 Recent Expansions: Distribution by Location of Facility
Figure 13.5 Recent Expansions: Distribution by Type of Expansion and Location of Facility
Figure 13.6 Recent Expansions: Distribution by Expanded Facility Area (square feet)
Figure 13.7 Recent Expansions: Distribution by Expanded Scale of Operation
Figure 13.8 Most Active Players: Distribution by Number of Expansions
Figure 13.9 Recent Expansions: Year-wise Trend by Geography, 2016-2021
Figure 13.10 Recent Expansions: Distribution by Geography
Figure 15.1 Clinical Trial Analysis: Methodology Used for Shortlisting Trials
Figure 15.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, 2013-2021
Figure 15.3 Clinical Trial Analysis: Distribution by Phase of Development
Figure 15.4 Clinical Trial Analysis: Distribution by Type of Oligonucleotide
Figure 15.5 Clinical Trial Analysis: Distribution by Phase of Development and Type of Oligonucleotide
Figure 15.6 Clinical Trial Analysis: Distribution by Trial Registration Year and Type of Oligonucleotide, 2013-2021
Figure 15.7 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 15.8 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Recruitment Status
Figure 15.9 Clinical Trial Analysis: Most Popular Keywords
Figure 15.10 Clinical Trial Analysis: Distribution by Study Design
Figure 15.11 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Figure 15.12 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year, 2012-2020
Figure 15.13 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Figure 15.14 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year and Enrolled Patient Population, 2012-2021
Figure 15.15 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Trial Recruitment Status, Pre- and Post-2017
Figure 15.16 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 15.17 Most Active Industry Players: Distribution by Number of Trials Registered
Figure 15.18 Most Active Non-Industry Players: Distribution by Number of Trials Registered
Figure 16.1 Global Installed Oligonucleotide Manufacturing Capacity: Distribution by Size of Manufacturer (Sample Data Set)
Figure 16.2 Global Installed Oligonucleotide Manufacturing Capacity: Distribution by Size of Manufacturer (Kilograms)
Figure 16.3 Global Installed Oligonucleotide Manufacturing Capacity: Distribution by Range
Figure 16.4 Global Installed Oligonucleotide Manufacturing Capacity: Distribution by Scale of Operation (Kilograms)
Figure 16.5 Global Installed Oligonucleotide Manufacturing Capacity: Distribution by Location of Manufacturing Facility (Kilograms)
Figure 17.1 Global Demand for Oligonucleotide Manufacturing (Kilograms)
Figure 17.2 Global, Commercial Demand for Oligonucleotide Manufacturing (Kilograms)
Figure 17.3 Global, Commercial Demand for Oligonucleotide Manufacturing: Distribution by Type of Oligonucleotide (Kilograms)
Figure 17.4 Global, Commercial Demand for Oligonucleotide Manufacturing: Distribution by Target Therapeutic Area (Kilograms)
Figure 17.5 Global, Commercial Demand for Oligonucleotide Manufacturing: Distribution by Geography (Kilograms)
Figure 17.6 Global, Clinical Demand for Oligonucleotide Manufacturing (Kilograms)
Figure 17.7 Global, Clinical Demand for Oligonucleotide Manufacturing: Distribution by Type of Oligonucleotide (Kilograms)
Figure 17.8 Global, Clinical Demand for Oligonucleotide Manufacturing: Distribution by Phase of Development (Kilograms)
Figure 17.9 Global, Clinical Demand for Oligonucleotide Manufacturing: Distribution by Target Therapeutic Area (Kilograms)
Figure 17.10 Global, Clinical Demand for Oligonucleotide Manufacturing: Distribution by Geography (Kilograms)
Figure 17.11 Global Oligonucleotide Manufacturing: Demand and Supply (Scenario 1), 2021-2030
Figure 17.12 Global Oligonucleotide Manufacturing: Demand and Supply (Scenario 2), 2021-2030
Figure 17.13 Global Oligonucleotide Manufacturing: Demand and Supply (Scenario 3), 2021-2030
Figure 18.1 Global Oligonucleotide Manufacturing Market, 2021-2031 (USD Million)
Figure 18.2 Custom Oligonucleotide Manufacturing Market, 2021-2031 (USD Million)
Figure 18.3 Large-scale Oligonucleotide Manufacturing Market, 2021-2031 (USD Million)
Figure 18.4 Oligonucleotide Manufacturing Market, 2021-2031: Distribution by Type of Oligonucleotide Manufactured, 2021-2031 (USD Million)
Figure 18.5 Oligonucleotide Manufacturing Market for Antisense Oligonucleotides, 2021-2031 (USD Million)
Figure 18.6 Oligonucleotide Manufacturing Market for miRNA, 2021-2031 (USD Million)
Figure 18.7 Oligonucleotide Manufacturing Market for shRNA, 2021-2031 (USD Million)
Figure 18.8 Oligonucleotide Manufacturing Market for siRNA, 2021-2031 (USD Million)
Figure 18.9 Oligonucleotide Manufacturing Market for Other Oligonucleotides, 2021-2031 (USD Million)
Figure 18.10 Oligonucleotide Manufacturing Market for Clinical Scale Operations, 2021-2031 (USD Million)
Figure 18.11 Oligonucleotide Manufacturing Market for Commercial Scale Operations, 2021-2031 (USD Million)
Figure 18.12 Oligonucleotide Manufacturing Market for In-house Operations, 2021-2031 (USD Million)
Figure 18.13 Oligonucleotide Manufacturing Market for Outsourced Operations, 2021-2031 (USD Million)
Figure 18.14 Oligonucleotide Manufacturing Market for Active Pharmaceutical Ingredients, 2021-2031 (USD Million)
Figure 18.15 Oligonucleotide Manufacturing Market for Finished Dosage Form, 2021-2031 (USD Million)
Figure 18.16 Oligonucleotide Manufacturing Market, 2021-2031: Distribution by Target Therapeutic Area, 2021 (USD Million)
Figure 18.17 Oligonucleotide Manufacturing Market for Autoimmune Disorders, 2021-2031 (USD Million)
Figure 18.18 Oligonucleotide Manufacturing Market for Cardiovascular Disorders, 2021-2031 (USD Million)
Figure 18.19 Oligonucleotide Manufacturing Market for Genetic Disorders, 2021-2031 (USD Million)
Figure 18.20 Oligonucleotide Manufacturing Market for Infectious Diseases, 2021-2031 (USD Million)
Figure 18.21 Oligonucleotide Manufacturing Market for Metabolic Disorders, 2021-2031 (USD Million)
Figure 18.22 Oligonucleotide Manufacturing Market for Neuromuscular Disorders, 2021-2031 (USD Million)
Figure 18.23 Oligonucleotide Manufacturing Market for Oncological Disorders, 2021-2031 (USD Million)
Figure 18.24 Oligonucleotide Manufacturing Market for Ophthalmic Disorders, 2021-2031 (USD Million)
Figure 18.25 Oligonucleotide Manufacturing Market for Other Therapeutic Areas, 2021-2031 (USD Million)
Figure 18.26 Oligonucleotide Manufacturing Market, 2021-2031: Distribution by Size of Manufacturer (USD Million)
Figure 18.27 Oligonucleotide Manufacturing Market for Small Companies, 2021-2031 (USD Million)
Figure 18.28 Oligonucleotide Manufacturing Market for Mid-sized Companies, 2021-2031 (USD Million)
Figure 18.29 Oligonucleotide Manufacturing Market for Large Companies, 2021-2031 (USD Million)
Figure 18.30 Oligonucleotide Manufacturing Market, 2021-2031: Distribution by Geography, 2021 and 2031 (USD Million)
Figure 18.31 Oligonucleotide Manufacturing Market in North America, 2021-2031 (USD Million)
Figure 18.32 Oligonucleotide Manufacturing Market in Europe, 2021-2031 (USD Million)
Figure 18.33 Oligonucleotide Manufacturing Market in Asia-Pacific and Rest of the World, 2021-2031 (USD Million)
Figure 19.1 Oligonucleotide Manufacturing Market: COVID-19 Impact Scenario, 2021-2031 (USD Million)
Figure 20.1 Oligonucleotide Manufacturing: SWOT Analysis
Figure 20.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 21.1 Survey Insights: Distribution by Type of Organization
Figure 21.2 Survey Insights: Distribution by Location of Organization
Figure 21.3 Survey Insights: Distribution by Seniority Level of Respondents
Figure 21.4 Survey Insights: Distribution by Type of Offering
Figure 21.5 Survey Insights: Distribution by Application
Figure 21.6 Survey Insights: Distribution by Location of Manufacturing Facilities
Figure 21.7 Survey Insights: Distribution by Extent of Outsourcing
Figure 21.8 Survey Insights: Distribution by Current Market Opportunity
Figure 23.1 Concluding Remarks: Market Landscape
Figure 23.2 Concluding Remarks: Clinical Trial Analysis
Figure 23.3 Concluding Remarks: Likely Partner Analysis
Figure 23.4 Concluding Remarks: Company Competitiveness Analysis
Figure 23.5 Concluding Remarks: Recent Initiatives
Figure 23.6 Concluding Remarks: Capacity Analysis
Figure 23.7 Concluding Remarks: Demand Analysis
Figure 23.8 Concluding Remarks: Market Forecast and Opportunity Analysis

List Of Tables

Table 4.1 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: List of Industry Players
Table 4.2 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Information on Location of Manufacturing Facilities and Regulatory Accreditations / Certifications Received
Table 4.3 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Information on Type of Oligonucleotide Manufactured and Type of Offering
Table 4.4 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Information on Type of Manufacturing Service(s) Offered
Table 4.5 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Information on Type of Modification(s) Offered and Type of Purification Method(s) Used
Table 5.1 Oligonucleotide Manufacturers Focused on Therapeutic Applications: List of Industry Players
Table 5.2 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Information on Location of Manufacturing Facilities and Regulatory Accreditations / Certifications Received
Table 5.3 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Information on Type of Oligonucleotide Manufactured and Type of Offering
Table 5.4 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Information on Type of Manufacturing Service(s) Offered
Table 5.5 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Information on Type of Modification(s) Offered and Type of Purification Method(s) Used
Table 8.1 Ajinomoto Bio-Pharma Services: Key Highlights
Table 8.2 Ajinomoto Bio-Pharma Services: Service Portfolio
Table 8.3 Ajinomoto Bio-Pharma Services: Manufacturing Facilities and Capabilities
Table 8.4 Ajinomoto Bio-Pharma Services: Recent Developments and Future Outlook
Table 8.5 Integrated DNA Technologies: Key Highlights
Table 8.6 Integrated DNA Technologies: Service Portfolio
Table 8.7 Integrated DNA Technologies: Manufacturing Facilities and Capabilities
Table 8.8 Integrated DNA Technologies: Recent Developments and Future Outlook
Table 8.9 Sigma Aldrich: Key Highlights
Table 8.10 Sigma Aldrich: Service Portfolio
Table 8.11 Sigma Aldrich: Manufacturing Facilities and Capabilities
Table 8.12 Sigma Aldrich: Recent Developments and Future Outlook
Table 8.13 Thermo Fisher Scientific: Key Highlights
Table 8.14 Thermo Fisher Scientific: Service Portfolio
Table 8.15 Thermo Fisher Scientific: Manufacturing Facilities and Capabilities
Table 8.16 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 8.17 BioSpring: Key Highlights
Table 8.18 BioSpring: Service Portfolio
Table 8.19 BioSpring: Manufacturing Facilities and Capabilities
Table 8.20 Kaneka Eurogentec: Key Highlights
Table 8.21 Kaneka Eurogentec: Service Portfolio
Table 8.22 Kaneka Eurogentec: Manufacturing Facilities and Capabilities
Table 8.23 Microsynth: Key Highlights
Table 8.24 Microsynth: Service Portfolio
Table 8.25 Microsynth: Manufacturing Facilities and Capabilities
Table 8.26 Sumitomo Chemical: Key Highlights
Table 8.27 Sumitomo Chemical: Service Portfolio
Table 8.28 Sumitomo Chemical: Manufacturing Facilities and Capabilities
Table 9.1 Agilent Technologies: Key Highlights
Table 9.2 Agilent Technologies: Service Portfolio
Table 9.3 Agilent Technologies: Manufacturing Facilities and Capabilities
Table 9.4 Agilent Technologies: Recent Developments and Future Outlook
Table 9.5 Nitto Denko Avecia: Key Highlights
Table 9.6 Nitto Denko Avecia: Service Portfolio
Table 9.7 Nitto Denko Avecia: Manufacturing Facilities and Capabilities
Table 9.8 Nitto Denko Avecia: Recent Developments and Future Outlook
Table 9.9 TriLink Biotechnologies: Key Highlights
Table 9.10 TriLink Biotechnologies: Service Portfolio
Table 9.11 TriLink Biotechnologies: Manufacturing Facilities and Capabilities
Table 9.12 TriLink Biotechnologies: Recent Developments and Future Outlook
Table 9.13 CordenPharma: Key Highlights
Table 9.14 CordenPharma: Service Portfolio
Table 9.15 CordenPharma: Manufacturing Facilities and Capabilities
Table 9.16 CordenPharma: Recent Developments and Future Outlook
Table 9.17 LGC, Biosearch Technologies: Key Highlights
Table 9.18 LGC, Biosearch Technologies: Service Portfolio
Table 9.19 LGC, Biosearch Technologies: Manufacturing Facilities and Capabilities
Table 9.20 LGC, Biosearch Technologies: Recent Developments and Future Outlook
Table 9.21 Lonza: Key Highlights
Table 9.22 Lonza: Service Portfolio
Table 9.23 Lonza: Manufacturing Facilities and Capabilities
Table 9.24 STA Pharmaceutical: Key Highlights
Table 9.25 STA Pharmaceutical: Service Portfolio
Table 9.26 STA Pharmaceutical: Manufacturing Facilities and Capabilities
Table 9.27 STA Pharmaceutical: Recent Developments and Future Outlook
Table 11.1 Big Pharma Players: List of Oligonucleotide Manufacturing Initiatives
Table 12.1 Oligonucleotide Manufacturers: List of Partnerships, 2014-2021
Table 12.2 Oligonucleotide Manufacturers: Leading Players in Terms of Number of Partnerships Established with Different Types of Partners
Table 12.3 Most Active Players: Geographical Distribution by Type of Partnership Model
Table 12.4 Oligonucleotide Manufacturers: Key Value Drivers
Table 13.1 Oligonucleotide Manufacturers: List of Expansions, 2016-2021
Table 14.1 Likely Partner Opportunities for Antisense Oligonucleotide Manufactures
Table 14.2 Likely Partner Opportunities for siRNA Therapeutics Manufacturers
Table 14.3 Likely Partner Opportunities for miRNA Therapeutics Manufacturers
Table 14.4 Likely Partner Opportunities for shRNA and sshRNA Therapeutics Manufacturers
Table 16.1 Global Installed Oligonucleotide Manufacturing Capacity: Average Capacity by Size of Manufacturer (Sample Data Set)
Table 16.2 Global Installed Oligonucleotide Manufacturing Capacity: Distribution by Size of Manufacturer
Table 17.1 Global Installed Oligonucleotide Manufacturing Demand (Scenario 1), 2021-2031 (Kilograms)
Table 17.2 Global Installed Oligonucleotide Manufacturing Demand (Scenario 2), 2021-2031 (Kilograms)
Table 17.3 Global Installed Oligonucleotide Manufacturing Demand (Scenario 3), 2021-2031 (Kilograms)
Table 21.1 Survey Insights: Overview of Respondents
Table 21.2 Survey Insights: Information on Seniority Level of Respondents
Table 21.3 Survey Insights: Information on Type of Offering
Table 21.4 Survey Insights: Information on Application
Table 21.5 Survey Insights: Information on Oligonucleotide Manufacturing Capacity
Table 21.6 Survey Insights: Number and Location of Manufacturing Facilities
Table 21.7 Survey Insights: Information on Extent of Outsourcing
Table 21.8 Survey Insights: Current Market Opportunity (USD Million)
Table 22.1 Hanugen Therapeutics: Key Highlights
Table 22.2 Axolabs: Key Highlights
Table 22.1 IBA Life Sciences: Key Highlights
Table 22.2 BianoScience: Key Highlights
Table 24.1 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Year of Establishment
Table 24.2 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Company Size
Table 24.3 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Scale of Operation
Table 24.4 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Company Size and Scale of Operation
Table 24.5 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Headquarters (Region-wise)
Table 24.6 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Manufacturing Facilities (Country-wise)
Table 24.7 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Regulatory Accreditations / Certifications Received
Table 24.8 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Oligonucleotide Manufactured
Table 24.9 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Offering
Table 24.10 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Company Size and Type of Offering
Table 24.11 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Oligonucleotide Manufactured and Type of Offering
Table 24.12 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Year of Establishment, Company Size and Type of Offering
Table 24.13 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Manufacturing Service(s) Offered
Table 24.14 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Modification(s) Offered
Table 24.15 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Purification Method(s) Used
Table 24.16 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Year of Establishment
Table 24.17 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Company Size
Table 24.18 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Scale of Operation
Table 24.19 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Company Size and Scale of Operation
Table 24.20 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Headquarters (Region-wise)
Table 24.21 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Manufacturing Facilities (Country-wise)
Table 24.22 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Regulatory Accreditations / Certifications Received
Table 24.23 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Oligonucleotide Manufactured
Table 24.24 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Offering
Table 24.25 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Company Size and Type of Offering
Table 24.26 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Oligonucleotide Manufactured and Type of Offering
Table 24.27 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Year of Establishment, Company Size and Type of Offering
Table 24.28 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Manufacturing Service(s) Offered
Table 24.29 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Modification(s) Offered
Table 24.30 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Purification Method(s) Used
Table 24.31 Ajinomoto Bio-Pharma Services: Annual Revenues (JPY Billion)
Table 24.32 Thermo Fisher Scientific: Annual Revenues (USD Billion)
Table 24.33 Kaneka Eurogentec: Annual Revenues (JPY Billion)
Table 24.34 Sumitomo Chemical: Annual Revenues (JPY Billion)
Table 24.35 Agilent Technologies: Annual Revenues (USD Billion)
Table 24.36 Nitto Denko Avecia: Annual Revenues (USD Billion)
Table 24.37 Trilink Biotechnologies: Annual Revenues (USD Billion)
Table 24.38 Lonza: Annual Revenues (CHF Billion)
Table 24.39 STA Pharmaceutical: Annual Revenues (RMB Billion)
Table 24.40 Big Pharma Initiatives: Distribution by Year of Initiative
Table 24.41 Big Pharma Initiatives: Distribution by Type of Initiative
Table 24.42 Big Pharma Initiatives: Distribution by Type of Oligonucleotide Manufactured
Table 24.43 Partnerships and Collaborations: Cumulative Distribution by Year of Partnership, 2014-2021
Table 24.44 Partnerships and Collaborations: Distribution by Type of Partnership
Table 24.45 Partnerships and Collaborations: Year-wise Trend by Type of Partnership, 2014-2021
Table 24.46 Partnerships and Collaborations: Distribution by Type of Partner
Table 24.47 Most Active Players: Distribution by Number of Partnerships
Table 24.48 Most Active Players: Geographical Distribution by Number of Partnerships
Table 24.49 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 24.50 Mergers and Acquisitions: Distribution by Year of Merger / Acquisition
Table 24.51 Mergers and Acquisitions: Distribution by Type of Acquisition
Table 24.52 Mergers and Acquisitions: Key Value Drivers
Table 24.53 Recent Expansions: Distribution by Year of Expansion, 2016-2021
Table 24.54 Recent Expansions: Distribution by Type of Expansion
Table 24.55 Recent Expansions: Distribution by Type Expansion and Purpose of Expansion
Table 24.56 Recent Expansions: Distribution by Location of Facility
Table 24.57 Recent Expansions: Distribution by Type of Expansion and Location of Facility
Table 24.58 Recent Expansions: Distribution by Expanded Facility Area (square feet)
Table 24.59 Recent Expansions: Distribution by Expanded Scale of Operation
Table 24.60 Most Active Players: Distribution by Number of Expansions
Table 24.61 Recent Expansions: Year-wise Trend by Geography, 2016-2021
Table 24.62 Recent Expansions: Distribution by Geography
Table 24.63 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, 2013-2021
Table 24.64 Clinical Trial Analysis: Distribution by Phase of Development
Table 24.65 Clinical Trial Analysis: Distribution by Type of Oligonucleotide
Table 24.66 Clinical Trial Analysis: Distribution by Phase of Development and Type of Oligonucleotide
Table 24.67 Clinical Trial Analysis: Distribution by Trial Registration Year and Type of Oligonucleotide, 2013-2021
Table 24.68 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table 24.69 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Recruitment Status
Table 24.70 Clinical Trial Analysis: Distribution by Study Design
Table 24.71 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Table 24.72 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year, 2012-2020
Table 24.73 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Table 24.74 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year and Enrolled Patient Population, 2012-2021
Table 24.75 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Trial Recruitment Status, Pre- and Post-2017
Table 24.76 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 24.77 Most Active Industry Players: Distribution by Number of Trials Registered
Table 24.78 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 24.79 Global Installed Oligonucleotide Manufacturing Capacity: Distribution by Size of Manufacturer (Sample Data Set)
Table 24.80 Global Installed Oligonucleotide Manufacturing Capacity: Distribution by Size of Manufacturer (Kilograms)
Table 24.81 Global Installed Oligonucleotide Manufacturing Capacity: Distribution by Scale of Operation (Kilograms)
Table 24.82 Global Installed Oligonucleotide Manufacturing Capacity: Distribution by Location of Manufacturing Facility (Kilograms)
Table 24.83 Global Demand for Oligonucleotide Manufacturing (Kilograms)
Table 24.84 Global, Commercial Demand for Oligonucleotide Manufacturing (Kilograms)
Table 24.85 Global, Commercial Demand for Oligonucleotide Manufacturing: Distribution by Type of Oligonucleotide (Kilograms)
Table 24.86 Global, Commercial Demand for Oligonucleotide Manufacturing: Distribution by Target Therapeutic Area (Kilograms)
Table 24.87 Global, Commercial Demand for Oligonucleotide Manufacturing: Distribution by Geography (Kilograms)
Table 24.88 Global, Clinical Demand for Oligonucleotide Manufacturing (Kilograms)
Table 24.89 Global, Clinical Demand for Oligonucleotide Manufacturing: Distribution by Type of Oligonucleotide (Kilograms)
Table 24.90 Global, Clinical Demand for Oligonucleotide Manufacturing: Distribution by Phase of Development (Kilograms)
Table 24.91 Global, Clinical Demand for Oligonucleotide Manufacturing: Distribution by Target Therapeutic Area (Kilograms)
Table 24.92 Global, Clinical Demand for Oligonucleotide Manufacturing: Distribution by Geography (Kilograms)
Table 24.93 Global Oligonucleotide Manufacturing: Demand and Supply (Scenario 1), 2021-2031
Table 24.94 Global Oligonucleotide Manufacturing: Demand and Supply (Scenario 2), 2021-2031
Table 24.95 Global Oligonucleotide Manufacturing: Demand and Supply (Scenario 3), 2021-2031
Table 24.96 Overall Oligonucleotide Manufacturing Market, 2021-2031 (USD Million)
Table 24.97 Custom Oligonucleotide Manufacturing Market, 2021-2031 (USD Million)
Table 24.98 Large-scale Oligonucleotide Manufacturing Market, 2021-2031 (USD Million)
Table 24.99 Oligonucleotide Manufacturing Market, 2021-2031: Distribution by Type of Oligonucleotide Manufactured, 2021-2031 (USD Million)
Table 24.100 Oligonucleotide Manufacturing Market for Antisense Oligonucleotides, 2021-2031 (USD Million)
Table 24.101 Oligonucleotide Manufacturing Market for miRNA, 2021-2031 (USD Million)
Table 24.102 Oligonucleotide Manufacturing Market for shRNA, 2021-2031 (USD Million)
Table 24.103 Oligonucleotide Manufacturing Market for siRNA, 2021-2031 (USD Million)
Table 24.104 Oligonucleotide Manufacturing Market for Other Oligonucleotides, 2021-2031 (USD Million)
Table 24.105 Oligonucleotide Manufacturing Market for Clinical Scale Operations, 2021-2031 (USD Million)
Table 24.106 Oligonucleotide Manufacturing Market for Commercial Scale Operations, 2021-2031 (USD Million)
Table 24.107 Oligonucleotide Manufacturing Market for In-house Manufacturing Operations, 2021-2031 (USD Million)
Table 24.108 Oligonucleotide Manufacturing Market for Outsourced Manufacturing Operations, 2021-2031 (USD Million)
Table 24.109 Oligonucleotide Manufacturing Market for Active Pharmaceutical Ingredients, 2021-2031 (USD Million)
Table 24.110 Oligonucleotide Manufacturing Market for Finished Dosage Form, 2021-2031 (USD Million)
Table 24.111 Oligonucleotide Manufacturing Market, 2021-2031: Distribution by Target Therapeutic Area, 2021 (USD Million)
Table 24.112 Oligonucleotide Manufacturing Market for Autoimmune Disorders, 2021-2031 (USD Million)
Table 24.113 Oligonucleotide Manufacturing Market for Cardiovascular Disorders, 2021-2031 (USD Million)
Table 24.114 Oligonucleotide Manufacturing Market for Genetic Disorders, 2021-2031 (USD Million)
Table 24.115 Oligonucleotide Manufacturing Market for Infectious Diseases, 2021-2031 (USD Million)
Table 24.116 Oligonucleotide Manufacturing Market for Metabolic Disorders, 2021-2031 (USD Million)
Table 24.117 Oligonucleotide Manufacturing Market for Neuromuscular Disorders, 2021-2031 (USD Million)
Table 24.118 Oligonucleotide Manufacturing Market for Oncological Disorders, 2021-2031 (USD Million)
Table 24.119 Oligonucleotide Manufacturing Market for Ophthalmic Disorders, 2021-2031 (USD Million)
Table 24.120 Oligonucleotide Manufacturing Market for Other Therapeutic Disorders, 2021-2031 (USD Million)
Table 24.121 Oligonucleotide Manufacturing Market, 2021-2031: Distribution by Size of Manufacturer (USD Million)
Table 24.122 Oligonucleotide Manufacturing Market for Small Companies, 2021-2031 (USD Million)
Table 24.123 Oligonucleotide Manufacturing Market for Mid-sized Companies, 2021-2031 (USD Million)
Table 24.124 Oligonucleotide Manufacturing Market for Large Companies, 2021-2031 (USD Million)
Table 24.125 Oligonucleotide Manufacturing Market, 2021-2031: Distribution by Geography, 2021 and 2031 (USD Million)
Table 24.126 Oligonucleotide Manufacturing Market in North America, 2021-2031 (USD Million)
Table 24.127 Oligonucleotide Manufacturing Market in Europe, 2021-2031 (USD Million)
Table 24.128 Oligonucleotide Manufacturing Market in Asia-Pacific and Rest of the World, 2021-2031 (USD Million)
Table 24.129 Oligonucleotide Manufacturing Market, 2021-2031: COVID-19 Impact Scenario (USD Million)
Table 24.130 Survey Insights: Distribution by Type of Organization
Table 24.131 Survey Insights: Distribution by Location of Organization
Table 24.132 Survey Insights: Distribution by Seniority Level of Respondents
Table 24.133 Survey Insights: Distribution by Type of Offering
Table 24.134 Survey Insights: Distribution by Application
Table 24.135 Survey Insights: Distribution by Location of Manufacturing Facilities
Table 24.136 Survey Insights: Distribution by Extent of Outsourcing
Table 24.137 Survey Insights: Distribution by Current Market Opportunity

List Of Companies

The following companies and organizations have been mentioned in the report.

  1. AAT Bioquest
  2. Abacus dx
  3. Abbott
  4. ACGT
  5. Advy Chemical
  6. Agilent Technologies
  7. AITbiotech
  8. Ajinomoto Bio-Pharma Services
  9. Alcami
  10. Alexion Pharmaceuticals
  11. Allianz BioInnovation
  12. Alnylam Pharmaceuticals
  13. AltaBioscience
  14. AM Chemicals
  15. Amgen
  16. AmpTec
  17. Amylon Therapeutics
  18. AnHeart Therapeutics
  19. Antisense Therapeutics
  20. Applied Biological Materials
  21. Aptahem
  22. Arbutus Biopharma
  23. Argonaut Manufacturing Services
  24. ARIZ Precision Medicine
  25. Ark Biosciences
  26. Arrowhead Pharmaceuticals
  27. Ascentage Pharma
  28. Ascletis Pharma 
  29. AstraZeneca
  30. Asymchem
  31. ATDBio
  32. Atlantic Healthcare
  33. ATZ Labs
  34. AUM LifeTech 
  35. Aurigene Pharmaceutical Services
  36. Averica Discovery Services (Acquired by Neopharm Labs)
  37. Avidity Biosciences
  38. Avrio Biopharmaceuticals
  39. Axolabs
  40. Bachem
  41. Bayer
  42. BeiGene
  43. Beta Pharma
  44. BianoScience
  45. Bio Basic
  46. Biogen
  47. Biolegio
  48. Biomics Biopharma
  49. Bioneer
  50. BioNTech
  51. Bio-Path Holdings
  52. BioServe Biotechnologies
  53. BioSpring
  54. Bio-Synthesis
  55. bluebird bio
  56. BOC Sciences
  57. Boehringer Ingelheim 
  58. Boston Children’s Hospital
  59. BR Biochem Life Sciences
  60. Bridgen
  61. Bristol Myers Squibb
  62. Brooks Automation
  63. Cancer Genetics
  64. Celsion
  65. ChemGenes
  66. Children's Hospital of Philadelphia
  67. City of Hope National Medical Center
  68. Clear Labs
  69. CMIC Group
  70. CordenPharma
  71. Creative Biogene
  72. Creative Biolabs
  73. CUSABIO TECHNOLOGY
  74. CyberGene
  75. Daiichi Sankyo
  76. Dalton Pharma Services
  77. Danaher
  78. Deep Genomics
  79. Dharmacon
  80. Dicerna Pharmaceuticals
  81. Dizal Pharmaceutical
  82. Drugs for Neglected Disease Initiative (DNDi)
  83. Dynacure
  84. Eli Lilly
  85. Elim Biopharmaceuticals
  86. Eton Bioscience
  87. Eurofins Genomics
  88. Fujimoto Chemicals
  89. Future synthesis
  90. GCC Biotech
  91. GE Healthcare
  92. Genbiotech
  93. Gene Universal
  94. GeneDesign
  95. Genei Laboratories
  96. GenePharma
  97. General Biosystems
  98. Generi Biotech
  99. GeneTx Biotherapeutics
  100. GENEWIZ
  101. GeneWorks
  102. Genomics
  103. GenScript
  104. Genzyme
  105. Glen Research
  106. Gradalis
  107. Granules OmniChem (Acquired by Ajinomoto Bio-Pharma)
  108. GSK
  109. Guang'anmen Hospital of China Academy of Chinese Medical Sciences
  110. Hanugen Therapeutics
  111. Hölzel Diagnostika
  112. Hugel
  113. Ildong Pharmaceutical
  114. Impact Therapeutics
  115. inqaba biotec
  116. Institute of Molecular and Cell Biology (IMCB), A*STAR
  117. Integrated DNA Technologies
  118. InteRNA Technologies
  119. Irvine Pharmaceutical Services (Acquired by Nitto Avecia Pharma)
  120. Isarna Therapeutics
  121. iTherapeutics
  122. Janssen
  123. Kaneka Eurogentec
  124. KareBay Biochem
  125. Korea Institute of Toxicology
  126. LC Sciences
  127. LGC Biosearch Technologies
  128. Lonza
  129. LubioScience
  130. Macrogen
  131. Mallinckrodt Pharmaceuticals
  132. Massachusetts General Hospital: The center for Computational and Integrative Biology
  133. Massachusetts Institute of Technology
  134. MBC BioLabs
  135. MBiotech
  136. MD Anderson Cancer Center
  137. Medigene
  138. Merck
  139. metabion
  140. Microsynth
  141. Midland Certified Reagent Company
  142. miRagen Therapeutics
  143. miReven
  144. Moligo Technologies
  145. MultiplexDX
  146. National Cancer Institute (NCI)
  147. Netherlands Organisation for Health Research and Development (ZonMw)
  148. NeuBase Therapeutics
  149. Nippon Shinyaku
  150. Nitto Denko Avecia
  151. n-Lorem Foundation
  152. Novartis
  153. Novatia
  154. NZYTech
  155. Oligomer Biotechnology
  156. OliX Pharmaceuticals
  157. Oncotelic Therapeutics
  158. Osaka International Cancer Institute
  159. Pace Analytical Services
  160. Pfizer
  161. Phio Pharmaceuticals
  162. Primetech
  163. ProQR Therapeutics
  164. PYC Therapeutics
  165. QIAGEN
  166. Quark Pharmaceuticals
  167. Quintara Biosciences
  168. Radboud University 
  169. Regen BioPharma
  170. Regulus Therapeutics
  171. ReproCell
  172. RiboBio
  173. Roche
  174. Rockland Immunochemicals
  175. RogCon Biosciences
  176. Sanofi
  177. Sanofi Active Ingredients Solutions
  178. Sanofi Genzyme 
  179. Sarepta Therapeutics
  180. Scandinavian Gene Synthesis (SGS DNA)
  181. Science Exchange
  182. SCIEX
  183. Secarna
  184. Seikagaku
  185. Servier
  186. Severn Biotech
  187. SGS
  188. Shanghai Zerun Biotechnology
  189. Sherlock Biosciences
  190. Sigma-Aldrich
  191. Silence Therapeutics
  192. Silenseed 
  193. Sirnaomics
  194. Soluventis 
  195. SomaGenics
  196. SomaLogic
  197. ST Pharm
  198. STA Pharmaceutical
  199. Sterna Biologicals
  200. Stoke Therapeutics
  201. Sumitomo Chemical
  202. Sunomix Biosciences
  203. Suzhou Ribo Life Science
  204. Sylentis
  205. Synbio Technologies
  206. Syngene
  207. t2cure
  208. TAG Copenhagen
  209. Takara Bio USA
  210. tebu-bio
  211. The Medicines Company
  212. Thermo Fisher Scientific
  213. Transgene Biotek
  214. TriLink Biotechnologies
  215. Twist Bioscience
  216. University of Maryland Global Campus (UMGC)
  217. University of Pennsylvania
  218. University of Sheffield
  219. University of Virginia School of Medicine
  220. UT Southwestern Medical Center
  221. ValueGene
  222. Vir Biotechnology 
  223. Vivantis Technologies
  224. VWR (Acquired by Avantor)
  225. Wave Life Sciences
  226. Wings Therapeutics
  227. Xcelris Labs
  228. Yale School of Medicine
  229. YuYu Pharma
  230. Zhejiang Haichang Biotechnology

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com